Leiomyosarcoma Research Articles and News- Updates:
March 7, 2017:
- Community Healthcare Systems Seeking To Incorporate Genetic Testing Into Cancer Care They Offer:
The Wall Street Journal (3/6, Kincaid, Subscription Publication, 6.37M) reports community healthcare systems are seeking to incorporate genetic testing into the cancer care they provide. Richard Schilsky, chief medical officer of the American Society of Clinical Oncology, points out that most patients with cancer receive care in a community setting, though testing tumors for multiple genetic mutations has been more prevalent in academic settings where oncologists have the resources to interpret complicated results.CHECK WITH YOUR OWN ONCOLOGIST IF YOU ARE INTERESTED IN PURSUING THIS.
February 20, 2017:
- Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial-The expression level of specific microRNAs in soft tissue sarcoma tissue samples might predict response to eribulin. Click here for the full study
February 7, 2017:
- Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment:https://www.ncbi.nlm.nih.gov/pubmed/28174295
February 3, 2017:
- The Value of Adaptive Preoperative Radiotherapy in Management of Soft Tissue Sarcoma: https://www.ncbi.nlm.nih.gov/pubmed/28169043
January 31, 2017:
- Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study: https://www.ncbi.nlm.nih.gov/pubmed/28163887
January 19, 2017:
- OncLive Insights Videos from three research oncologists
- Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the role of radiomics in the treatment landscape of sarcoma. Radiomics, which is a fairly new field of study, quantifies complex aspects of tumor images related to tumor biology. Prior research has validated its use in predicting patient outcomes in lung and head and neck cancers. According to Pollack, sarcoma may be an ideal treatment landscape in which to study radiomics because so many patients with this disease already undergo MRIs as part of their overall treatment. This essentially provided the rationale for examining radiomics in this particular patient population. In his research, Pollack found that, after patients’ tumor images were analyzed through a list of radiomic features, the model that was made to predict outcomes was extremely accurate. In fact, it was found to be more accurately predictive than other standard factors, such as those based on tumor grade, tumor size, and other clinical features. – See more at: http://www.onclive.com/onclive-tv/dr-pollack-on-the-role-of-radiomics-in-sarcoma#sthash.XFZMhYEU.dpuf
December 3, 2016:
- Response to anti-PD1 therapy with nivolumab in metastatic sarcomas: https://www.ncbi.nlm.nih.gov/pubmed/28169043
- 2016 CTOS Annual Meeting in Libson, Portugal: The National Leiomyosarcoma Foundation represented the LMS Community at the 2016 Connective Tissue Oncology Conference in Lisbon, Portugal. Dr. Achee and I traveled to Portugal on our own to represent LMS patients and their families, as is the case for all conferences as well as patient programs hosted in cities across the United States and abroad by the Foundation. The landmark $1 million dollar Collaborative International LMS Research Project, initiated by the Liddy Shriver Initiative, was discussed at a special session hosted by the Liddy Shriver Initiative, who brought together the esteemed researchers for such a large scale research project, which launched in August. This session was to brief other researchers at the conference who also have an interest in LMS research efforts and perhaps already involved in research projects of their own. This is truly a “gift of hope” on a global scale for the LMS community. We are so thankful for the opportunity, and grateful to Bruce and Beverly Shriver – the Liddy Shriver Initiative – for bringing us all together for such a promising research breakthrough potential and ultimately to make a difference for hopeful acceleration of treatment advancements for the future. We salute all who could come together to support the vision and mission of this particular Liddy Shriver initiative. The Shriver family has for so many years, contributed so much to the Sarcoma Community in tribute to their daughter who was lost to Ewings Sarcoma. Their tireless work promoting research ideas and endeavors, and bringing together key researchers for each project for various sarcoma subtypes has been truly the definition of “proactive passion.” It goes without saying that they are highly respected by the medical research community. The National Leiomyosarcoma Foundation will receive updates on the inroads made from this recently co-funded LMS research project as well as other continuous updates on medical research efforts, clinical trials, and related youtube presentations through www.nlmsf.org. Additionally, your contribution to the website through your voice – adds hope for patients and families everywhere – your voice matters! We thank you all for you continued interest, support, and contribution to the efforts being made by foundations that honor you, represent you, and work tirelessly on behalf of the LMS Community.The link below is a briefing of the LMS research project – a brief summary of the initial ACOR announcement of this project in August and Sept. powerpoint Lisbon Portugal Briefing on the LMS Collaborative International LMS Research Project: updated-maximizing-therapeutic-response-in-leiomyosarcoma
- Scientists develop cancer therapy that reduces toxic chemotherapy effects. https://www.mdlinx.com/oncology/article/670?utm_source=in-house&utm_medium=message&utm_campaign=lf-onc-nov16
October 24, 2016:
- FDA Approves Merck’s KEYTRUDA (pembrolizumab) in metastatic non-small cell lung cancer (NSCLC) for First-Line treatment of patients whose tumors have high programmed death-ligand 1 (PD-L1) expression with no genomic tumor aberrations (EGFR or ALK ). http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-metastatic-nsclc-
October 19th, 2016:
- FDA Approves Lartruvo for adults with a subtype of STS for which an anthracycline-containing regimen is pertinent, and which cannot be cured with radiotherapy or surgery. Approval was granted based on safety and effectiveness data from the Phase 2 JGDG trial of 133 patients. https://www.drugs.com/history/lartruvo.html
- The FDA has approved olaratumab (Lartruvo) for soft-tissue sarcoma when used with doxorubicin (Adriamycin) as first-line treatment. (In other words, you don’t have to do other drugs first.) This is the first “first-line” treatment approved for sarcoma in 40 years. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm525878.htm
October 14, 2016:
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomized, double-blind, placebo-controlled, phase 2 trial. Patients and Families- Click the Link “The Lancet Oncology” to read the rest of the article. This is important information to discuss with your oncologist /oncology medical team. http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30507-1/abstract
October 10, 2016:
- Neoadjuvant anthracycline plus ifosfamide chemotherapy was linked to significantly increased survival rates in patients with soft tissue sarcomas located in the torso or extremities who were at high risk of recurrence. Click here for more information.
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. Click here for the abstract.
October 07, 2016:
Trabectedin Improves PFS vs Best Supportive Care in Sarcoma
Trabectedin significantly improves progression-free survival in patients with pretreated advanced soft tissue sarcomas.
Click here for more information.
October 1, 2016:
- High expression of proteasome activator complex subunit 1 (PSME1) is associated with poor survival in soft tissue leiomyosarcoma patients and might be used to predict the likely course of the disease.
Click here for more information on the study.
- The BMC ( British Journal of Cancer) features an article on molecular classification of uterine leiomyosarcomas. Their data supports the existence of distinct leiomyosarcoma subgroups which are clinically associated with tumor grades. These findings will help advance the classification of leiomyosarcomas and promote more individualized treatments. Click here for the abstract.
August 8, 2016:
- The Liddy Shriver Sarcoma Initiative is funding a $1 million international collaborative grant for leiomyosarcoma (LMS) research. The two-year project will enlist investigators from France, Germany, and the United States with the aim of identifying new therapies and starting clinical trials for the most prevalent and clinically challenging types of LMS.
The Grant Announcement – “$1 Million Study on Leiomyosarcoma Set to Begin” –http://bit.ly/2bcT1iq
The Experimental Plan Article – Maximizing Therapeutic Response in Leiomyosarcoma –http://bit.ly/2aSLxR2
For more information, visit the website http://sarcomahelp.org/leiomyosarcoma-collaborative-research.html
- A study exploring chromosomal abnormalities in uterine smooth muscle tumors found that uterine leiomyomas with abnormal nuclei and leiomyosarcomas are closely related. Click here for the abstract.
- A study published by the BJC found that antiapoptotic (anti-cell death) Bc1-2 family proteins are highly expressed in soft tissue leiomyosarcomas and inhibition of these proteins increases tumor sensitivity to chemotherapy. Click here for the abstract.
- The journal BMC Cancer features an article about Trabectedin and inoperable or recurrent soft tissue sarcomas. Their data suggest there may be some benefit in using trabectedin, particularly in patients with leiomyo- or liposarcoma who failed standard of care agents.Click here to view abstract or click here to link to free full text article.
- Dr. Hussein Tawbi, formerly of the Pittsburgh Cancer Research Center and currently at MD Anderson, has pioneered two important treatment advancements not only in Sarcoma but also in Melanoma. Tawbi is leading a three-year study on the effectiveness of pembrolizumab. Dr. Tawbi spoke in 2013 at the National Leiomyosarcoma Foundation’s conference for patients and families. Click to read full article at the Pittsburgh Business Times.
- Eli Lilly and Company Clinical Trial for soft tissue sarcoma involving their developing of Olaratumab in combination with Doxorubicin for patients with advanced metastatic disease can be viewed here: https://clinicaltrials.gov/ct2/show/NCT02451943
- Doctors discuss liver problems with Trabectedin (Yondelis), which may be the second or third drug tried in leiomyosarcoma patients. This interview was done before the drug got FDA approval. http://www.onclive.com/peer-exchange/soft-tissue-sarcoma/trabectedin-in-soft-tissue-sarcoma
- There’s excitement that palbociclib, approved by the FDA for some types of breast cancer, may be useful in other cancers. It inhibits CDK4 & 6, which also are present in LMS. The following article says we need more research before we get too excited: http://www.healthnewsreview.org/news-release-review/new-breast-cancer-drug-may-effective-types-cancer/
- Promising results from early investigation of a new injectable agent was developed at MIT that creates a “fluorescent probe” to image cancer cells to aid in surgical removal of all cancerous tissue on the first attempt. More on Lumicell’s product: http://www.medicalnewstoday.com/articles/304776.php